Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2008-09-11
2011-10-11
Schultz, Doug (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024500, C435S006120, C435S325000, C435S375000
Reexamination Certificate
active
08034792
ABSTRACT:
Methods of treating a tumor in a subject include identifying a subject having, at risk for, or suspected of having a tumor, and administering to the subject an effective amount of an IGFBP7 agent if the tumor has increased Ras-BRAF-MEK-Erk signaling, is dependent for growth and/or survival upon the Ras-BRAF-MEK-Erk signaling pathway, and/or expresses an activated or oncogenic BRAF or RAS.
REFERENCES:
patent: 2004/0005294 (2004-01-01), Lee
patent: 2005/0148509 (2005-07-01), Dake et al.
patent: 2006/0084603 (2006-04-01), Kirman et al.
patent: 2006/0100144 (2006-05-01), Lang et al.
patent: 2006/0211073 (2006-09-01), May et al.
patent: 2007/0060607 (2007-03-01), Bartkovitz et al.
patent: WO 03/001985 (2003-01-01), None
patent: WO 2005/066371 (2005-07-01), None
patent: WO 2005/085861 (2005-09-01), None
Pritchard et al. Biochem Soc Trans. Nov. 2007; 35(Pt 5): 1329-1333.
Peyssonnaux et al. 2001, Biol. Cell 93, 53-62.
Akaogi et al., “Synergistic growth stimulation of mouse fibroblasts by tumor-derived adhesion factor with insulin-like growth factors and insulin,” Cell Growth Differ.,7:1671-77 (1996).
Alsina et al., “Detection of mutations in the mitogen-activated protein kinase pathway in human melanoma,” Clin. Cancer Res., 9:6419-25 (2003).
Burger et al., “Down-regulation of T1A12/mac25, a novel insulin-like growth factor binding protein related gene, is associated with disease progression in breast carcinomas,” Oncogene, 16:2459-67 (1998).
Burger et al., “Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer,” Eur. J. Cancer, 41:1515-27 (2005).
Burger et al., “Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations,” Eur Urol. 50:1102-09 (2006).
Busby et al., “Detection of BRAF mutations in colorectal tumours and peritoneal washings using a mismatch ligation assay,” J. Clin. Pathol., 58: 372-375 (2005).
Chen et al., “Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) has potential tumour-suppressive activity in human lung cancer,” J. Pathol., 211:431-438 (2007).
Chien and Lowe, “Secreting tumor suppression,” Cell, 132:339-341 (2008).
Chung et al., “Detection of BRAFV600E mutation on fine needle aspiration specimen of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area,” Clin. Endocrinol(Oxf), 65:660-666 (2006).
Cohen et al., “Lack of BRAF mutation in primary uveal melanoma,” Invest. Ophthalmol. Vis. Sci. 44:28976-78 (2003).
Collado et al., “Senescence in premalignant tumours,” Nature, 436:642 (2005).
Davies et al., “Mutations of the BRAF gene in human cancer,” Nature, 417:949-954 (2002).
Deng et al., “BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer,” Clin. Cancer Res. 10:191-195 (2004).
Dhomen and Marais, “New insight into BRAF mutations in cancer,” Curr. Opin. Genet. Dev., 17:31-39 (2007).
Emley et al., “Oncogenic BRAF and the tumor suppressor IGFBP7 in the genesis of atypical spitzoid nevomelanocytic proliferations,” J. Cutan. Pathol., 37:344-349 (2009).
Fecher et al., “Toward a molecular classification of melanoma,” J. Clin. Oncol. 25:1606-20 (2007).
Fensterle et al., “B-Raf specific antibody responses in melanoma patients,” BMC Cancer, 4:62 (2004).
Fridman et al., “Epigenetic and functional analysis of IGFBP3 and IGFBPrP1 in cellular immortalization,” Biochem. Biophys. Res. Commun., 357:785-791 (2007).
Gazin et al., “An elaborate pathway required for Ras-mediated epigenetic silencing,” Nature, 449:1073-77 (2007).
Goldenberg et al., “The V599E BRAF mutation is uncommon in biliary tract cancers,” Mod. Pathol., 17:1386-91 (2004).
Goydos et al., “Detection of B-RAF and N-RAS mutations in human melanoma,” J. Am. Coll. Surg., 200:362-370 (2005).
Gray-Schopfer et al., “Melanoma biology and new targeted therapy,” Nature, 445:851-857 (2007).
Hayashida et al., “A rapid and simple detection method for the BRAF (T1796A) mutation in fine-needle aspirated thyroid carcinoma cells,” Thyroid, 14:910-915 (2004).
Hinselwood et al., “BRAF mutation detection and identification by cycling temperature capillary electrophoresis,” Electrophoresis, 26:2553-61 (2005).
Hoeflich et al., “Oncogenic BRAF is required for tumor growth and maintenance in melanoma models,” Cancer Res., 66:999-1006 (2006).
Ichii-Nakato et al., “High frequency of BRAFV600E mutation in acquired nevi and small congenital nevi, but low frequency of mutation in medium-sized congenital nevi,” J. Invest. Dermatol., 126:2111-18 (2006).
Ikenoue et al., “Rapid detection of mutations in the BRAF gene using real-time polymerase chain reaction and melting curve analysis,” Cancer Genet. Cytogenet, 149:68-71 (2004).
International Search Report and Written Opinion, International Application No. PCT/US2008/076043 mailed Mar. 25, 2009.
Kann et al., “Improved marker combination for detection of de novo genetic variation and aberrant DNA in colorectal neoplasia,” Clin. Chem. 52:2299-2302 (2006).
Kato et al., “A follistatin-like gene, mac25, may act as a growth suppressor of osteosarcoma cells,” Oncogene, 12:1361-64 (1996).
Kato, “A secreted tumor-suppressor, mac25, with activin-binding activity,” Mol. Med., 6:126-135 (2000).
Kawakami et al., “Immunological detection of altered signaling molecules involved in melanoma development,” Cancer Metastasis Rev., 24:357-366 (2005).
Kim et al., “Development and applications of a BRAF oligonucleotide microarray,” J. Mol. Diagn., 9:55-63 (2007).
Kim et al., “Identification of a Family of Low-Affinity Insulin-Like Growth Factor Binding Proteins (IGFBPs): Characterization of Connective Tissue Growth Factor as a Member of the IGFBP Superfamily,” Proc. Natl. Acad. Sci. USA, 94:12981-86 (1997).
Kumagai et al., “Clinical Implications of Pre-Operative Rapid BRAF Analysis for Papillary Thyroid Cancer,” Endocr. J., 54:399-405 (2007).
Lee et al., “BRAF mutations in non-Hodgkin's lymphoma,” Br. J. Cancer, 10:1958-60 (2003).
Leppa et al., “Differential regulation of c-Jun by ERK and JNK during PC12 cell differentiation,” EMBO J., 17:4404-13 (1998).
Lilleberg et al., “High sensitivity scanning of colorectal tumors and matched plasma DNA for mutations in APC, TP53, K-RAS, and BRAF genes with a novel DHPLC fluorescence detection platform,” Ann N.Y. Acad. Sci, 1022:250-256 (2004).
Masson, et al., “Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E,” Mol. Cell. Probes., 18:349-352 (2004).
Matsubara et al., “Impact of radiation and docetaxel on anti-tumor effects of insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) in hormone-refractory human prostate cancer cells,” Proceedings of the American Association for Cancer Research Annual Meeting 48 p1258 (2007).
Matsukuma, et al., “Rapid and simple detection of hot spot point mutations of epidermal growth factor receptor, BRAF, and NRAS in cancers using the loop-hybrid mobility shift assay,” J. Mol. Diagn., 8:504-512 (2006).
Michaloglou et al., “BRAFE600-associated senescence-like cell cycle arrest of human naevi,” Nature, 436:720-724 (2005).
Murphy et al., “Identification and Characterization of Genes Differentially Expressed In Meningiomas,” Cell Growth & Differentiation, 4:715-722 (1993).
Mutaguchi et al., “Restoration of insulin-like growth factor binding protein-related protein 1 has a tumor-suppressive activity through induction of apoptosis in human prostate cancer,” Cancer Res., 63:7717-23 (2003).
Namba e
Green Michael
Wajapeyee Narendra
Fish & Richardson P.C.
Schultz Doug
University of Massachusetts
LandOfFree
Insulin-like growth factor binding protein 7 for treatment... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Insulin-like growth factor binding protein 7 for treatment..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Insulin-like growth factor binding protein 7 for treatment... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4291821